Natural bryo is too expensive and hard to get for commercial use, so the little amount they have will only be used in clinical trials until they run out.
Synthetic bryo is the only version that can be commercialized, so without bioequivalence the company will go under.
They figured out bryo synthesis a few years ago though, so no one is worried about this being a problem. All they have to do is prove its bioequivalency in a short trial.
Market Data 
Markets 
AI
